Eintrag weiter verarbeiten
Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial: Study protocol f...
Gespeichert in:
| Zeitschriftentitel: | Medicine |
|---|---|
| Personen und Körperschaften: | , |
| In: | Medicine, 99, 2020, 3, S. e18829 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
Jung, Ga Hyeon Kang, Jae Hui Jung, Ga Hyeon Kang, Jae Hui |
|---|---|
| author |
Jung, Ga Hyeon Kang, Jae Hui |
| spellingShingle |
Jung, Ga Hyeon Kang, Jae Hui Medicine Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial General Medicine |
| author_sort |
jung, ga hyeon |
| spelling |
Jung, Ga Hyeon Kang, Jae Hui 0025-7974 1536-5964 Ovid Technologies (Wolters Kluwer Health) General Medicine http://dx.doi.org/10.1097/md.0000000000018829 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background:</jats:title> <jats:p>With the increase in the prevalence of chronic diseases, enhancing immunity has become an important challenge. Health functional foods, such as <jats:italic toggle="yes">Phellitus linteus</jats:italic> (PL), are known to improve immune function. In previous laboratory studies, it has been reported that PL has anticancer activities. In this study, we will evaluate if PL improves immune functions in adults with reduced immunity and identify its effects on immunity factors.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>This study will be a single-center, randomized, double-blinded, and placebo-controlled trial. Study participants will be randomly allocated to 3 experimental groups: those taking PL 1000 mg, PL 2000 mg, or placebo. Total duration of the clinical trial will be 8 to 10 weeks. Study participants will have follow-up visits every 4 weeks and the effect and safety will be assessed at the second and third visits. All participants will be asked to maintain a dosage schedule for this protocol. The primary outcome will be natural killer (NK) cell activity and the secondary outcomes will include peripheral white blood cell (WBC) count; levels of tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-1β, IL-2, IL-6, and IL-12 to assess autoimmune reactivity; and levels of immunoglobulin (Ig)G1, IgG2, and Immunoglobulin M (IgM) to assess allergic activity. Repeated measure analysis will be used to measure primary efficacy based on full analysis set.</jats:p> </jats:sec> <jats:sec> <jats:title>Discussion:</jats:title> <jats:p>This study has limited inclusion and exclusion criteria and a well-controlled intervention. It will be the first randomized controlled trial to assess the efficacy and safety of PL in adults with reduced immunity. This study will provide insights into the mechanisms underlying the immune-stimulating effects of PL and lay the groundwork for further studies.</jats:p> </jats:sec> Study protocol for a randomized, double-blinded, placebo-controlled pilot trial Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial Medicine |
| doi_str_mv |
10.1097/md.0000000000018829 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny9tZC4wMDAwMDAwMDAwMDE4ODI5 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny9tZC4wMDAwMDAwMDAwMDE4ODI5 |
| institution |
DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 2020 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 2020 |
| issn |
0025-7974 1536-5964 |
| issn_str_mv |
0025-7974 1536-5964 |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
jung2020efficacyofphellinuslinteussanghuangextractforimprovingimmunefunctionsstudyprotocolforarandomizeddoubleblindedplacebocontrolledpilottrialstudyprotocolforarandomizeddoubleblindedplacebocontrolledpilottrial |
| publishDateSort |
2020 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
Medicine |
| source_id |
49 |
| title_sub |
Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title |
Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_unstemmed |
Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_full |
Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_fullStr |
Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_full_unstemmed |
Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_short |
Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_sort |
efficacy of phellinus linteus (sanghuang) extract for improving immune functions : study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.1097/md.0000000000018829 |
| publishDate |
2020 |
| physical |
e18829 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>With the increase in the prevalence of chronic diseases, enhancing immunity has become an important challenge. Health functional foods, such as <jats:italic toggle="yes">Phellitus linteus</jats:italic> (PL), are known to improve immune function. In previous laboratory studies, it has been reported that PL has anticancer activities. In this study, we will evaluate if PL improves immune functions in adults with reduced immunity and identify its effects on immunity factors.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods:</jats:title>
<jats:p>This study will be a single-center, randomized, double-blinded, and placebo-controlled trial. Study participants will be randomly allocated to 3 experimental groups: those taking PL 1000 mg, PL 2000 mg, or placebo. Total duration of the clinical trial will be 8 to 10 weeks. Study participants will have follow-up visits every 4 weeks and the effect and safety will be assessed at the second and third visits. All participants will be asked to maintain a dosage schedule for this protocol. The primary outcome will be natural killer (NK) cell activity and the secondary outcomes will include peripheral white blood cell (WBC) count; levels of tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-1β, IL-2, IL-6, and IL-12 to assess autoimmune reactivity; and levels of immunoglobulin (Ig)G1, IgG2, and Immunoglobulin M (IgM) to assess allergic activity. Repeated measure analysis will be used to measure primary efficacy based on full analysis set.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Discussion:</jats:title>
<jats:p>This study has limited inclusion and exclusion criteria and a well-controlled intervention. It will be the first randomized controlled trial to assess the efficacy and safety of PL in adults with reduced immunity. This study will provide insights into the mechanisms underlying the immune-stimulating effects of PL and lay the groundwork for further studies.</jats:p>
</jats:sec> |
| container_issue |
3 |
| container_start_page |
0 |
| container_title |
Medicine |
| container_volume |
99 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792344388325605377 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:06:49.148Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Efficacy+of+Phellinus+linteus+%28sanghuang%29+extract+for+improving+immune+functions+%3A+Study+protocol+for+a+randomized%2C+double-blinded%2C+placebo-controlled+pilot+trial&rft.date=2020-01-01&genre=article&issn=1536-5964&volume=99&issue=3&pages=e18829&jtitle=Medicine&atitle=Efficacy+of+Phellinus+linteus+%28sanghuang%29+extract+for+improving+immune+functions+%3A+Study+protocol+for+a+randomized%2C+double-blinded%2C+placebo-controlled+pilot+trial&aulast=Kang&aufirst=Jae+Hui&rft_id=info%3Adoi%2F10.1097%2Fmd.0000000000018829&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792344388325605377 |
| author | Jung, Ga Hyeon, Kang, Jae Hui |
| author_facet | Jung, Ga Hyeon, Kang, Jae Hui, Jung, Ga Hyeon, Kang, Jae Hui |
| author_sort | jung, ga hyeon |
| container_issue | 3 |
| container_start_page | 0 |
| container_title | Medicine |
| container_volume | 99 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background:</jats:title> <jats:p>With the increase in the prevalence of chronic diseases, enhancing immunity has become an important challenge. Health functional foods, such as <jats:italic toggle="yes">Phellitus linteus</jats:italic> (PL), are known to improve immune function. In previous laboratory studies, it has been reported that PL has anticancer activities. In this study, we will evaluate if PL improves immune functions in adults with reduced immunity and identify its effects on immunity factors.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>This study will be a single-center, randomized, double-blinded, and placebo-controlled trial. Study participants will be randomly allocated to 3 experimental groups: those taking PL 1000 mg, PL 2000 mg, or placebo. Total duration of the clinical trial will be 8 to 10 weeks. Study participants will have follow-up visits every 4 weeks and the effect and safety will be assessed at the second and third visits. All participants will be asked to maintain a dosage schedule for this protocol. The primary outcome will be natural killer (NK) cell activity and the secondary outcomes will include peripheral white blood cell (WBC) count; levels of tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-1β, IL-2, IL-6, and IL-12 to assess autoimmune reactivity; and levels of immunoglobulin (Ig)G1, IgG2, and Immunoglobulin M (IgM) to assess allergic activity. Repeated measure analysis will be used to measure primary efficacy based on full analysis set.</jats:p> </jats:sec> <jats:sec> <jats:title>Discussion:</jats:title> <jats:p>This study has limited inclusion and exclusion criteria and a well-controlled intervention. It will be the first randomized controlled trial to assess the efficacy and safety of PL in adults with reduced immunity. This study will provide insights into the mechanisms underlying the immune-stimulating effects of PL and lay the groundwork for further studies.</jats:p> </jats:sec> |
| doi_str_mv | 10.1097/md.0000000000018829 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny9tZC4wMDAwMDAwMDAwMDE4ODI5 |
| imprint | Ovid Technologies (Wolters Kluwer Health), 2020 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 2020 |
| institution | DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105 |
| issn | 0025-7974, 1536-5964 |
| issn_str_mv | 0025-7974, 1536-5964 |
| language | English |
| last_indexed | 2024-03-01T17:06:49.148Z |
| match_str | jung2020efficacyofphellinuslinteussanghuangextractforimprovingimmunefunctionsstudyprotocolforarandomizeddoubleblindedplacebocontrolledpilottrialstudyprotocolforarandomizeddoubleblindedplacebocontrolledpilottrial |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | e18829 |
| publishDate | 2020 |
| publishDateSort | 2020 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | Medicine |
| source_id | 49 |
| spelling | Jung, Ga Hyeon Kang, Jae Hui 0025-7974 1536-5964 Ovid Technologies (Wolters Kluwer Health) General Medicine http://dx.doi.org/10.1097/md.0000000000018829 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background:</jats:title> <jats:p>With the increase in the prevalence of chronic diseases, enhancing immunity has become an important challenge. Health functional foods, such as <jats:italic toggle="yes">Phellitus linteus</jats:italic> (PL), are known to improve immune function. In previous laboratory studies, it has been reported that PL has anticancer activities. In this study, we will evaluate if PL improves immune functions in adults with reduced immunity and identify its effects on immunity factors.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>This study will be a single-center, randomized, double-blinded, and placebo-controlled trial. Study participants will be randomly allocated to 3 experimental groups: those taking PL 1000 mg, PL 2000 mg, or placebo. Total duration of the clinical trial will be 8 to 10 weeks. Study participants will have follow-up visits every 4 weeks and the effect and safety will be assessed at the second and third visits. All participants will be asked to maintain a dosage schedule for this protocol. The primary outcome will be natural killer (NK) cell activity and the secondary outcomes will include peripheral white blood cell (WBC) count; levels of tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-1β, IL-2, IL-6, and IL-12 to assess autoimmune reactivity; and levels of immunoglobulin (Ig)G1, IgG2, and Immunoglobulin M (IgM) to assess allergic activity. Repeated measure analysis will be used to measure primary efficacy based on full analysis set.</jats:p> </jats:sec> <jats:sec> <jats:title>Discussion:</jats:title> <jats:p>This study has limited inclusion and exclusion criteria and a well-controlled intervention. It will be the first randomized controlled trial to assess the efficacy and safety of PL in adults with reduced immunity. This study will provide insights into the mechanisms underlying the immune-stimulating effects of PL and lay the groundwork for further studies.</jats:p> </jats:sec> Study protocol for a randomized, double-blinded, placebo-controlled pilot trial Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial Medicine |
| spellingShingle | Jung, Ga Hyeon, Kang, Jae Hui, Medicine, Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial, General Medicine |
| title | Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_full | Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_fullStr | Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_full_unstemmed | Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_short | Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_sort | efficacy of phellinus linteus (sanghuang) extract for improving immune functions : study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_sub | Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| title_unstemmed | Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions : Study protocol for a randomized, double-blinded, placebo-controlled pilot trial |
| topic | General Medicine |
| url | http://dx.doi.org/10.1097/md.0000000000018829 |